GLP-1RA 和 SGLT-2i 在 2 型糖尿病女性患者中的心血管获益。
Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes.
机构信息
Department of Internal Medicine, East Carolina University, United States.
Department of Family Medicine, East Carolina University, United States.
出版信息
Prim Care Diabetes. 2022 Jun;16(3):471-473. doi: 10.1016/j.pcd.2022.03.012. Epub 2022 Apr 5.
Given the CV benefit noted in the CVOTs, GLP-1RAs and SGLT-2is are given preference in T2DM guidelines. While guidelines do not report potential gender difference, those differences exist. On restricting the CVOTs results to women with increased CV risk or established ASCVD, GLP-1RAs significantly reduced MACE while SGLT-2is resulted in a non-significant reduction.
鉴于 CVOT 中观察到的心血管获益，GLP-1RA 和 SGLT-2i 在 T2DM 指南中被优先推荐。虽然指南没有报告潜在的性别差异，但这些差异确实存在。将 CVOT 结果限制在心血管风险增加或已确诊 ASCVD 的女性中，GLP-1RA 显著降低了 MACE，而 SGLT-2i 则没有显著降低。
Zotero 插件